Topline Data for Oral Semaglutide in PIONEER 6 CV Outcomes Trial An investigational oral form of the GLP-1 agonist semaglutide for type 2 diabetes has demonstrated safety for the overall MACE endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results